Impact of Serum Levels of IL-18 and Soluble IL-2 Receptor on the Clinical Outcome of Patients With Diffuse Large B-cell Lymphoma Treated with R-CHOP Regimen

References

• Al-HamadaniM , HabermannTM , CerhanJRet al.Non-Hodgkin lymphoma subtype distribution, geodemographic patterns and survival in the US: a longitudinal analysis of the National Cancer Data B se from 1998 to 2011. Am. J. Hematol.90(9), 790–795 (2015).
   PubMed Web of Science ®Google Scholar
• EL-BolkainyM , AkramM , GoudaIet al.Lymphoma In: Pathology of Cancer . 4th Edition. 200–204 (2013).
   Google Scholar
• ShippM. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N. Engl. J. Med.329, 987–994 (1993).
   PubMed Web of Science ®Google Scholar
• SehnLH , BerryB , ChhanabhaiMet al.The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood109, 1857–1861 (2007).
   PubMed Web of Science ®Google Scholar
• GotoN , TsurumiH , GotoHet al.Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Ann. Hematol.91(5), 705–714 (2012).
   PubMed Web of Science ®Google Scholar
• FukumotoH , NishioM , NishioKet al.Interferon-γ-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Jap. J. Cancer Res.88(5), 501–505 (1997).
   PubMedGoogle Scholar
• KawabataT , IchikuraT , MajimaTet al.Preoperative serum IL-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer92(8), 2050–2055 (2001).
   PubMed Web of Science ®Google Scholar
• PagèsF , BergerA , HengleinBet al.Modulation of IL-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int. J. Cancer84(3), 326–330 (1999).
   PubMed Web of Science ®Google Scholar
• TakuboT , KumuraT , NakaoTet al.Comparative study on complete remission rate and overall survival in three groups classified based on the serum IL-18 level in non-Hodgkin’s lymphoma patients. Acta Haematol.104(4), 220–222 (2000).
   PubMed Web of Science ®Google Scholar
• O’SheaJJ , GadinaM , SiegelRM. Cytokines and cytokine receptors in: clinical immunology, Fifth Edition. 127–155 (2019).
   Google Scholar
• WagnerDK , KiwanukaJ , EdwardsBet al.Soluble IL-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J. Clin. Oncol.5(8), 1262–1274 (1987).
   PubMed Web of Science ®Google Scholar
• VivianiS , CameriniE , BonfanteVet al.Soluble IL-2 receptors (sIL-2R) in Hodgkin’s disease: outcome and clinical implications. Br. J. Cancer77(6), 992 (1998).
   PubMed Web of Science ®Google Scholar
• SemenzatoG , FoaR , AgostiniCet al.High serum levels of soluble IL-2 receptor in patients with B chronic lymphocytic leukemia. Blood70(2), 396–400 (1987).
   PubMed Web of Science ®Google Scholar
• YasudaN , LaiPK , IpSHet al.Soluble IL-2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood71(4), 1021–1026 (1988).
   PubMed Web of Science ®Google Scholar
• KitagawaJI , HaraT , TsurumiHet al.Serum-soluble IL-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J. Cancer Res. Clin. Oncol.135(1), 53–59 (2009).
   PubMed Web of Science ®Google Scholar
• GotoN , TsurumiH , TakemuraMet al.Serum IL-18Levels are associated with response to treatment and survival in patients with aggressive non-Hodgkin’s lymphoma (ASH Annual Meeting Abstracts). Blood104, 4543 (2004).
   Web of Science ®Google Scholar
• GotoH , TsurumiH , TakemuraMet al.Serum-soluble IL-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index. J. Cancer Res. Clin. Oncol.131(2), 73–79 (2005).
   PubMed Web of Science ®Google Scholar
• GotoN , TsurumiH , KasaharaSet al.Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Eur. J. Haematol.87(3), 217–227 (2011).
   PubMed Web of Science ®Google Scholar
• DlouhyI , FilellaX , RoviraJet al.High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. Leuk.Res.59, 20–25 (2017).
   PubMed Web of Science ®Google Scholar
• UminoK , FujiwaraSI , MinakataDet al.Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk. Lymphoma 59, 1–8 (2018).
   PubMedGoogle Scholar
• NicolaidesC , DimouS , PavlidisN. Prognostic factors in aggressive non-Hodgkin’s lymphomas. Oncologist3(3), 189–197 (1998).
   PubMedGoogle Scholar
• CharbonneauB , MaurerMJ , AnsellSMet al.Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine60(3), 882–889 (2012).
   PubMed Web of Science ®Google Scholar
• TomitaN , SakaiR , FujisawaSet al.SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma. Cancer Sci.103(8), 1518–1523 (2012).
   PubMed Web of Science ®Google Scholar
• RautL , ChakrabartiP. Management of relapsed-refractory diffuse large B-cell lymphoma. South Asian J. Cancer.3(1), 66 (2014).
   PubMedGoogle Scholar
• NovickD , SchwartsburdB , PinkusRet al.A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine14(6), 334–342 (2001).
   PubMed Web of Science ®Google Scholar
• BuflerP , AzamT , Gamboni-RobertsonFet al.A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl Acad. Sci. USA99(21), 13723–13728 (2002).
   PubMed Web of Science ®Google Scholar
• SoydincHO , GuneyN , BasaranMet al.Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin’s lymphoma patients. Genet. Mol. Res.15(3), Doi: 10.4238/gmr.15038590 (2016).
   PubMed Web of Science ®Google Scholar
• TomitaN , SuzukiT , MiyashitaKet al.The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma. Leuk. Lymphoma57(12), 2763–2770 (2016).
   PubMed Web of Science ®Google Scholar